Indication
HIV infection pre-exposure prophylaxis
HIV infection pre-exposure prophylaxis (PrEP) is a preventive biomedical indication designated for HIV-1-negative adults and adolescents who are at ongoing, substantial risk of acquiring human immunodeficiency virus through sexual intercourse or injection drug use. Read more about HIV infection pre-exposure prophylaxis
21 drugs 17 manufacturers
Drugs that treat it
Common HIV infection pre-exposure prophylaxis therapies.
DESCOVY (emtricitabine/tenofovir alafenamide fumarate)
VOCABRIA (cabotegravir sodium)
APRETUDE (cabotegravir)
EMTRICITABINE-TENOFOVIR DISOP (emtricitabine/tenofovir disoproxil fumarate)
EMTRICITABINE-TENOFOVIR DISOP (emtricitabine/tenofovir disoproxil fumarate)
EMTRICITABINE-TENOFOVIR DISOP (emtricitabine/tenofovir disoproxil fumarate)
EMTRICITABINE-TENOFOVIR DISOP (emtricitabine/tenofovir disoproxil fumarate)
EMTRICITABINE-TENOFOVIR DISOP (emtricitabine/tenofovir disoproxil fumarate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHIV infection pre-exposure prophylaxis (PrEP) is a preventive biomedical indication designated for HIV-1-negative adults and adolescents who are at ongoing, substantial risk of acquiring human immunodeficiency virus through sexual intercourse or injection drug use.
The intervention addresses potential systemic immune exposure, specifically guarding against mucosal and hematologic invasion by retroviral pathogens that target host CD4+ T lymphocytes and macrophages.
Pathophysiologically, the strategy establishes protective concentrations of antiretroviral agents in peripheral blood and genital or rectal tissues prior to viral inoculation.
This preventive state halts early reverse transcription and cellular integration, thereby blocking sustained viral replication and preventing the establishment of permanent systemic infection.
- cdc.gov
HIV infection pre-exposure prophylaxis (PrEP) is a preventive biomedical indication designated for HIV-1-negative adults and adolescents who are at ongoing, substantial risk of acquiring human immunodeficiency virus through sexual intercourse or injection drug use
- nih.gov
HIV infection pre-exposure prophylaxis (PrEP) is a preventive biomedical indication designated for HIV-1-negative adults and adolescents who are at ongoing, substantial risk of acquiring human immunodeficiency virus through sexual intercourse or injection drug use This preventive state halts early reverse transcription and cellular integration, thereby blocking sustained viral replication and preventing the establishment of permanent systemic infection
Personalize your experience
Follow HIV infection pre-exposure prophylaxis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.